ライフサイエンスコーパス: risk reduction

1 r mortality in preterm neonates (7% absolute-risk reduction).

2 strated a high 3-y efficacy of 71% (relative risk reduction).

3 for HR; P(heterogeneity) 0.037 for absolute risk reduction).

4 en possible, is important for prevention and risk reduction.

5 iation between antibody function and disease risk reduction.

6 t screening strategies would achieve greater risk reduction.

7 n fraction (OEF), which likely drives stroke risk reduction.

8 ideline-directed therapy, and cardiovascular risk reduction.

9 confidence interval: -0.3% to 4.6%) absolute risk reduction.

10 rd a new strategy for lipid-lowering and CVD risk reduction.

11 owing interest in nature-based solutions for risk reduction.

12 ns aimed at breast density and breast cancer risk reduction.

13 associated with CVD and all-cause mortality risk reduction.

14 and event rates along with trial-based event risk reduction.

15 and hs-cTnI identify candidates for targeted risk reduction.

16 ve CAD, may represent a novel target for CVD risk reduction.

17 treatment, with or without a 20% behavioral risk reduction.

18 e sessions to train their network members in risk reduction.

19 ial as a public health strategy aimed at CVD risk reduction.

20 tein cholesterol levels and magnitude of VTE risk reduction.

21 risk had intermediate risk and intermediate risk reduction.

22 cantly reduced that risk with large absolute risk reductions.

23 nt weighting (IPTW), and applying drug class risk reductions.

24 t impact on combined Breteau index (relative risk reduction 0.43, 95% CI 0.26 to 0.70) and on dengue

25 rd ratio 0.88, 95% CI 0.73 to 1.07, absolute risk reduction 0.8%, 95% CI -0.5 to 2.0).

26 [95% credible interval, 0.84-0.95]; absolute risk reduction, 0.38% [95% CI, 0.20%-0.55%]; number need

27 tio [OR], 0.93 [95% CI, 0.88-0.98]; absolute risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%)

28 ears; OR, 0.93 [95% CI, 0.88-0.99]; absolute risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%).

29 stream and upstream groups (percent absolute risk reduction: -0.46; 95% repeated confidence interval:

30 %, number needed to treat=42; no HF absolute risk reduction 1.0%, number needed to treat=103).

31 , which was lower than expected (ie, greater risk reduction); 1.01 (95% CI, 0.94-1.09) vs 0.90 (95% C

32 iagnosed with an infection with C difficile (risk reduction 2.4%, 95% CI -0.6 to 5.9; one-sided p=0.0

33 risk reduction in those with HF (HF absolute risk reduction 2.4%, number needed to treat=42; no HF ab

34 ST-associated afternoon and evening accident risk reductions [2, 5, 7].

35 10.7% to 7.0 and 8.0, respectively (absolute risk reductions: 3.7% and 2.7%, respectively).

36 observed in humans and demonstrated the same risk reduction (70%) previously attained in women with h

37 Absolute risk reductions (95% confidence intervals) differed acro

38 US subgroup demonstrated particularly robust risk reductions across a variety of individual and compo

39 ality, reaching a plateau with more than 50% risk reduction after an administration-to-birth interval

40 atelet drugs induce only a moderate relative risk reduction after atherothrombosis, and their inhibit

41 0.41, 95% CI 0.26-0.65) had significant VTE risk reduction after surgery with chemoprophylaxis.

42 ]), statin therapy led to a greater relative risk reduction among a subgroup at high genetic risk.

43 scribe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associ

44 thy lifestyle could lead to greater absolute risk reduction among those with high T2D-GR.

45 ultural priorities in international disaster risk reduction and adaptation efforts.

46 ng pregnancy is necessary for evidence-based risk reduction and adequate patient counseling.

47 ysis data on cardiovascular disease relative risk reduction and bleeding risk.

48 ular infections, physicians should regard on risk reduction and comply with etiologic approach of dia

49 native readmission metrics in strategies for risk reduction and cost savings.

50 en promoted for cardiovascular disease (CVD) risk reduction and for the prevention of cancer.

51 in development, climate adaptation, disaster risk reduction and insurance.

52 prevents informed public health guidance for risk reduction and mitigation strategies, e.g., the "6-f

53 to develop strategies for better screening, risk reduction and stratification, and outcome improveme

54 dations for mild asthma should consider both risk reduction and symptoms.

55 Thus, we compared ASCVD risk reduction and T2D incidence increases across 3 stat

56 duration that is based on considerations of risk reduction and tolerability was appropriate.

57 Management includes cardiovascular risk reduction and use of antiplatelet therapy, dependin

58 2), which was higher than expected (ie, less risk reduction); and 0.49 (95% CI, 0.34-0.71) vs 0.61 (9

59 m the cornerstone approach of cardiovascular risk reduction, and a higher high-density lipoprotein (H

60 ributions: water quality regulation, coastal risk reduction, and crop pollination.

61 es such as absolute risk reduction, relative risk reduction, and numbers needed to treat.

62 with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years

63 ions, although the magnitude of the ischemic risk reduction appeared to be enhanced with prasugrel.

64 However, although the absolute risk reductions appeared numerically larger in patients

65 on), and encourage the inclusion of relevant risk reduction approaches for cardiovascular disease in

66 0.46 [95% CI, 0.33-0.66]; I2 = 67%; absolute risk reduction [ARD], -2.0% [95% CI, -2.8% to -1.2%]).

67 tutional drivers of routines, efficiency and risk reduction are not mediated by clinical leadership w

68 se in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: -0.007, 0.018; P =

69 odds ratios (OR(adj)) and adjusted absolute risk reduction (ARR(adj)).

70 d with 47.3% in Group O [P < 0.001; absolute risk reduction (ARR) = 35.7%, 95% confidence interval (C

71 The absolute risk reduction (ARR) in cardiovascular events from thera

72 ent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P =

73 etic risk (hazard ratio [HR], 1.02; absolute risk reduction [ARR], -0.2%, P=0.86).

74 ar risk of 17.1% to 11.6% (model A; absolute risk reduction [ARR], 5.5%) or 6.5% (model B; ARR 10.6%)

75 Absolute risk reductions (ARRs) and numbers needed to treat (NNTs

76 affected sibling, and also compute Relative Risk Reduction as a function of risk score threshold.

77 are strategies by measuring effectiveness of risk reduction as a function of the features of projecte

78 ee of these factors may be linked to greater risk reduction as compared to the presence of one or non

79 For all outcomes, the risk reduction associated with ANS was transient, with i

80 omorbidity burden (2 and >/=3), the absolute risk reduction associated with CRT-D over ICD alone appe

81 P in predicting incident CKD and whether CKD risk reduction associates with progressive treatment-ind

82 nd risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL chol

83 We modeled expected risk reductions based on shorter-term effects observed i

84 risk and translating this understanding into risk-reduction behaviors.

85 gher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while

86 There were no significant differences in risk reduction between the TAU and screening phases (23%

87 edicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sa

88 nsoring or application of literature-derived risk reductions, but the exenatide versus placebo MACE e

89 6.0% and 1.5%, respectively, and a relative risk reduction by alirocumab of 37% in the high PRS grou

90 and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration.

91 ed with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment.

92 on, ticagrelor monotherapy demonstrated a 6% risk reduction, compared with conventional 12-month DAPT

93 t cause sudden infant death, the mainstay of risk reduction continues to be a safe sleep environment,

94 We evaluated a diabetes risk reduction diet (DRRD) and breast cancer risk.

95 Together, the studies quantify the risk reduction ecosystem services of marsh wetlands.

96 al management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure managemen

97 of Kaplan-Meier risk estimates and relative risk reduction estimates from previous trials.

98 conomic value of mangroves forests for flood risk reduction every 20 km worldwide.

99 Absolute risk reduction for a population with 2.5% incidence of p

100 was associated with an even more pronounced risk reduction for all-cause mortality (relative risk, 0

101 Dog ownership was associated with a 24% risk reduction for all-cause mortality as compared to no

102 lar mortality, dog ownership conferred a 31% risk reduction for cardiovascular death (relative risk,

103 ternational study predicted a nationwide 11% risk reduction for CMM after MIDP versus ODP, which is l

104 The absolute risk reduction for CMM was 11% (95% CI 7.3%-15%) at obse

105 The magnitude of expected risk reduction for each of these therapies must be weigh

106 tential biological advantages of hypothermia risk reduction for endothermic animals and spore spreadi

107 and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed

108 In patients with HF, the risk reduction for first HHF was similar for those with

109 controlled trial to ascertain the extent of risk reduction for in-hospital death in COVID-19.

110 The 5-year absolute risk reduction for ischemic stroke/systemic embolism wit

111 The absolute risk reduction for major adverse cardiovascular events w

112 or patients from outbreak ZIP codes, and (c) risk reduction for nonimmune patients.

113 outbreak ZIP codes, (b) education focused on risk reduction for patients from outbreak ZIP codes, and

114 This translated to a relative risk reduction for progression to kidney failure in CKD

115 Relative risk reduction for the primary endpoint was similar for

116 Relative risk reduction for the secondary endpoint was similar ac

117 Expected absolute risk reductions for antihypertensive and lipid-lowering

118 f epidemiological studies to derive relative risk reductions for each intervention.

119 t LDL-C-lowering trials demonstrated similar risk reductions for IS and CHD(8-10).

120 risk, patients with PAD had larger absolute risk reductions for the primary end point (3.5% with PAD

121 tutional capacity and governance can support risk reduction from extreme weather events.

122 ction of 3-year cardiovascular disease event risk reduction from intensive (target systolic blood pre

123 However, these findings do not indicate risk reduction from medications that inhibit HMG-CoA red

124 AL and other recent trials document coronary risk reduction from supplemental marine n-3 FAs but no c

125 supplemental marine n-3 FAs but no clear CVD risk reduction from supplemental vitamin D.

126 Conversely, predicted risk reduction from weight loss was strikingly similar a

127 respiratory disease, and other causes, with risk reductions from 17% to 47% for the highest versus l

128 where appropriate, aligning conservation and risk reduction goals.

129 trials (47.0%) were powered for an absolute risk reduction greater than or equal to 10%, but this ef

130 of 60 ml/min per 1.73 m(2) experienced a 12% risk reduction (hazard ratio [HR], 0.88; 95% confidence

131 without high genetic risk and a 31% relative risk reduction (HR, 0.69 [0.55-0.86], P=0.0012), and 4.0

132 In contrast, there was a 13% relative risk reduction (HR, 0.87 [0.75-0.998], P=0.047) and a 1.

133 ne eGFR of 45 ml/min per 1.73 m(2) had a 13% risk reduction (HR, 0.87; 95% CI, 0.78 to 0.98).

134 I, 0.67-0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78-1.22]).

135 Model-based odds ratios for PVC risk reduction in 2-day intervals of preop-AT ranged fro

136 109/L threshold was associated with absolute-risk reduction in all risk groups, varying from 4.9% in

137 .87, 0.79-0.96; p=0.007), and a 12% relative risk reduction in all-cause mortality (0.88, 0.81-0.95;

138 represented an intervention effect (absolute risk reduction in antibiotic prescribing) of -29% (95% C

139 A 12% relative risk reduction in cardiovascular disease events was used

140 for glycemic control did not confer a large risk reduction in cardiovascular events.

141 confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezeti

142 There was a pattern of greater absolute risk reduction in CV death/myocardial infarction/stroke

143 5% confidence interval 7.2%-28.1%), absolute risk reduction in developing postoperative infection, wi

144 e of antibodies to derive a serocorrelate of risk reduction in future seroepidemiological studies of

145 ding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trial

146 or dementia prevention research and targeted risk reduction in LMICs.

147 The relative risk reduction in MACE with ticagrelor was consistent fo

148 ose of docosahexaenoic acid and the relative risk reduction in major vascular events (RR 0.96 [95% CI

149 ministered was associated with a 7% relative risk reduction in major vascular events (RR, 0.93 [95% C

150 he CEC with a qualitatively similar relative risk reduction in MIs reported by the SI.

151 The absolute risk reduction in mortality associated with dynamic asse

152 pt of AET was associated with a 29% relative risk reduction in mortality.

153 rtation-related PA was associated with a 33% risk reduction in NAFLD.

154 isk elevation in WHI and in the direction of risk reduction in NHS.

155 ed with a 7.2% (95% CI, 4.1%-10.3%) absolute risk reduction in operative mortality; this association

156 r incorporate the concept of chronic disease risk reduction in order to improve public health.

157 ategories and even showed a greater relative risk reduction in patients in the low (<=60 kg; HR, 0.55

158 yocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease

159 evaluated, and strategies for enhanced ASCVD risk reduction in patients with IBD are outlined.

160 tatistically significant difference with the risk reduction in patients younger than 75 years (0.85 [

161 ars is still considered standard of care for risk reduction in premenopausal women who are at least 3

162 There was a gradient in relative risk reduction in primary events with sacubitril/valsart

163 showed a clinically relevant and significant risk reduction in the pirfenidone group compared with th

164 Marked 2- and 5-year risk reduction in the progression from CKD to kidney fai

165 treatment showed a significant 10% relative risk reduction in the three-point major adverse cardiova

166 OT, and JUPITER primary prevention, relative risk reduction in those at high genetic risk was 46% ver

167 lnerable to making first attempts and target risk reduction in those groups.

168 P for interaction 0.28) but larger absolute risk reduction in those with HF (HF absolute risk reduct

169 between individual and group mechanisms for risk reduction in uncertain environments, and we raise s

170 of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95

171 ODYSSEY OUTCOMES demonstrated a 31% relative risk reduction in VTE with PCSK9 inhibition (HR, 0.69 [9

172 y associated with incident AF with a greater risk reduction in women (hazard ratio per SD, 0.86; 95%

173 Risk reductions in 3M-CDP and 6M-CDP were 77.2% (p=0.007

174 umab was associated with consistent relative risk reductions in both risk categories (hazard ratio=0.

175 The relative risk reductions in cardiovascular death/hospitalization

176 relationship between the exercise volume and risk reductions in cardiovascular morbidity and mortalit

177 The relative and absolute risk reductions in HHF with the sodium-glucose cotranspo

178 ODP, but was not powered to assess potential risk reductions in major morbidity.

179 Greater absolute risk reductions in the renal composite outcome were obse

180 lar arrhythmia burden with modest short-term risks, reduction in antiarrhythmic drug use, and improve

181 6, and 0.62, respectively), whereas absolute risk reductions increase (SBP: 1.1%, 2.3%, 5.4%, 10.3%,

182 ent cancer in unsuspecting relatives through risk-reduction intervention in mutation carriers and to

183 Culturally specific risk reduction interventions for Hispanic women should f

184 ASCVD risk-reduction interventions including statin therapy in

185 The relative risk reduction is similar in patients with and without c

186 iveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90

187 w-dose dabigatran, the net benefit (absolute risk reduction minus absolute risk increase) was positiv

188 The Cardiovascular Risk Reduction Model was developed by Million Hearts and

189 o evaluate the Million Hearts Cardiovascular Risk Reduction Model.

190 risk, 0.98; 95% CI, 0.68-1.42; 0.3% absolute risk reduction, moderate certainty), serious complicatio

191 d by total estrogen levels, with the largest risk reductions occurring in women in the highest tertil

192 0.53 [0.29-0.99], p=0.048), with an absolute risk reduction of 1.12% (95% CI 0.62-1.56).

193 ing of SSBs with water was associated with a risk reduction of 10% (HR: 0.90; 95% CI: 0.85, 0.95).ASB

194 .4% in the home oxygen alone group, absolute risk reduction of 17.0% (95% CI, 0.1%-34.0%).

195 e attempt risk (23% vs 18%), with a relative risk reduction of 20%.

196 ol intake and all-cause death with a maximal risk reduction of 21% (95% confidence interval, 5%-34%)

197 lyses on shunt dependency showed an absolute risk reduction of 24% for the intervention (LD, 2.2% [1

198 ients aged 55 years or older had an absolute risk reduction of 3.3% (CI, 2.3% to 4.3%), with a lower

199 n vs 205 [19%] of 1055 for control, absolute risk reduction of 3.46%, 95% CI 0.21-6.73%, p=0.038) By

200 e, the high compliance group had an absolute risk reduction of 3.6% (P < 0.01), 2.9% (P < 0.01) and 1

201 tatin therapy was associated with a relative risk reduction of 44% (95% confidence interval [CI], 22-

202 with water was associated with a significant risk reduction of 5% (HR: 0.95; 95% CI: 0.91, 0.99), whe

203 Based on previously reported data (relative risk reduction of 50%), the incremental gain in quality-

204 survival up to 1 year postoperatively with a risk reduction of 57% (hazard ratio = 0.43, 95% confiden

205 f protein associated with a maximum relative risk reduction of 62.4% (95% CI, 33.1 to 78.9; P<0.01).

206 This corresponded to a relative risk reduction of 68.8%.

207 6, 95% CI 0.54-0.59, p < 0.001) and a 5-year risk reduction of 8.3 per 1,000 (95% CI 7.8-8.9, p < 0.0

208 k of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2%

209 1, P = 0.02), which translates to a relative risk reduction of 89.1%.

210 isorder), with estimates suggesting relative risk reduction of 9% to 58% for these outcomes.

211 essure is important in the prevention and/or risk reduction of cardiometabolic disorders for both men

212 arch in, implementation of, and advocacy for risk reduction of cardiovascular disease in the global c

213 ed trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use o

214 nary event, or nonfatal stroke, the relative risk reduction of combination therapy compared with mono

215 y; and the IgG threshold associated with 90% risk reduction of IGbsD derived by estimating absolute d

216 ally-derived GBS serotype-Ia and III IgG and risk reduction of IGbsD in infants' <=90 days of age.

217 inst a serological threshold associated with risk reduction of IGbsD.

218 0% (95% confidence interval [CI], 45.8-62.7) risk reduction of laboratory-confirmed influenza infecti

219 demonstrated a 10% stronger association with risk reduction of NAFLD in women, women showed a lower t

220 however, there is a consistent 15% relative-risk reduction of nonfatal myocardial infarction.

221 The magnitude of risk reduction of perinatal mortality remains uncertain.

222 Risk reduction of progression to T2DM by level of attend

223 ical management regarding the assessment and risk reduction of select pediatric populations at high r

224 .04 and >=1.53ug/ml were associated with 90% risk reduction of serotype-Ia and III IGbsD, respectivel

225 or morbidity outcome, whereas a significant risk reduction of severe neonatal brain injury was assoc

226 I) 0.27-0.72; P = 0.001) was associated with risk reduction of SSI.

227 emaining free of BF for 3 years had relative risk reductions of 39% for OS and 73% for PCSS.

228 The absolute risk reductions of COPD-related rehospitalization in the

229 ll lead to greater understanding of specific risks, reduction of exposures, and improvement of health

230 Overall, no risk reduction on major adverse cardiovascular events wa

231 immune correlate associated with GBS disease risk reduction on the basis of studies of natural infect

232 cant, 0.63% absolute risk and 11.9% relative risk reductions on the 3-year (2014-2016) cumulative inc

233 ipophilic statins were associated with a CRC risk reduction (OR 0.78; 95%CI 0.66-0.96, p = 0.018).

234 on of SPI1, was strongly associated with MPM risk reduction (OR = 0.60; 95% CI = 0.45-0.81; p = 0.000

235 he treatment phase was accompanied by an HCV risk reduction-oriented behavioral intervention.

236 with occasional partners were offered a HCV risk reduction-oriented behavioral intervention.

237 normoglycaemia (1.2%, -0.3 to 2.7; absolute risk reduction p(interaction)=0.0019).

238 ine Lp(a) concentration and magnitude of VTE risk reduction (P(interaction)=0.04).

239 o were never hospitalized (trend in absolute risk reduction: p(interaction) = 0.050).

240 ce interval: 0.80 to 1.24; trend in relative risk reduction: p(interaction) = 0.15).

241 c251, resulting in a vaccine efficacy (i.e., risk reduction per exposure) of 68%.

242 Moreover, the risk reduction potential of foods was calculated by mult

243 ese findings can be used to develop targeted risk reduction programs for gastric adenocarcinoma.

244 On the other hand, the advantage of neutron risk reduction proposed by NCEPT was found to give no co

245 , 0.22-1.53]; n = 4738; I2 = 66.3%; absolute risk reduction range, -3.1% to -13.1%).

246 r-sexual provisioning, kin provisioning, and risk reduction reciprocity, three levels of cooperation

247 ion to effect size measures such as absolute risk reduction, relative risk reduction, and numbers nee

248 levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.

249 fidence interval (CI) = 19.1-52.4%; relative risk reduction (RRR) = 67.8%] and success rate of NGI in

250 tain summarised dose-response data (relative risk reduction [RRR]) and multivariate meta-regression t

251 Application of literature-derived risk reductions showed no meaningful changes in MACE or

252 The development of effective risk reduction strategies for aquatic pollutants require

253 to guide patient education about lymphedema risk reduction strategies for those who undergo bilatera

254 w biomarker to optimize patient care, target risk reduction strategies, and administer neuroprotectiv

255 cation with sexual partners especially about risk reduction strategies, including preexposure prophyl

256 Closer monitoring and risk-reduction strategies for cardiovascular comorbid co

257 (Cardiovascular Risk Reduction Study [Reduction in Recurrent Major CV Di

258 he two techniques, or how to follow up after risk reduction surgery.The aim of the second part of the

259 However, in the overall population, the risk reduction tended to be greater for those with EF <=

260 failure were more similar, but the absolute risk reductions tended to be greater: 1.9% (8.6% versus

261 ector and adopting an ecological approach to risk reduction that addresses personal, societal, and cu

262 ndomized trials on relative and absolute CVD risk reduction that can occur when antihypertensive trea

263 or-positive first breast cancer, an absolute risk reduction that is consistent with findings from cli

264 ical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied

265 t whether a THRIVES (Tailored Hospital-based Risk reduction to Impede Vascular Events after Stroke) i

266 exemestane, or raloxifene for breast cancer risk reduction to premenopausal women.

267 ernal sera IgG threshold associated with 90% risk reduction was >=2.31 and >=3.41ug/ml for serotype-I

268 With alirocumab, the corresponding absolute risk reduction was 1.4% (95% confidence interval [CI]: 0

269 ecombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% (p = 0.32) in patients with sep

270 <0.001), whereas in all others, the relative risk reduction was 24% (95% CI, 8-37; P=0.004) despite s

271 The absolute risk reduction was 9.8% (95% CI, 8.2% to 18.9%), with a

272 The magnitude of the cardiovascular risk reduction was comparable with the benefit seen in c

273 sease event by the age of 75 years, and this risk reduction was greater the earlier cholesterol conce

274 We hypothesized that risk reduction was higher for infection-related cancer a

275 days), and 3.4% (91 to 180 days), whereas no risk reduction was observed in patients screened >180 da

276 A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus

277 The magnitude of risk reduction was similar in epsilon4 noncarriers with

278 Absolute risk reductions were 25% (95% CI 6-41) for low-dose vers

279 Absolute risk reductions were also greater in subgroups with base

280 Consequently, absolute risk reductions were greater in subgroups with higher ba

281 s across the risk scores (25%-34%), absolute risk reductions were greater in those at higher baseline

282 For myocardial infarction, the greatest risk reductions were in blacks (HR, 0.23 [95% CI, 0.11-0

283 Risk reductions were most apparent among women whose pri

284 Risk reductions were slightly smaller for past users but

285 es for setting DRIs based on chronic disease risk reduction will be applied for the first time during

286 pressures and heart failure hospitalization risk reduction with a novel implantable PA pressure moni

287 syndrome and a larger absolute and relative risk reduction with alirocumab treatment, providing an i

288 ies was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab was 0.4% (95% CI: -0.1% t

289 hese patients did not have a significant VTE risk reduction with chemoprophylaxis.

290 Furthermore, a gradient of more pronounced risk reduction with edoxaban was observed with greater s

291 to investigate potential mediators of cancer risk reduction with immediate cART.

292 e in analysis 4 visually stabilized at a 25% risk reduction with increasingly narrower CIs (-46% to +

293 Relative risk reduction with statin therapy has been consistent a

294 Across all 3 studies, the absolute risk reduction with statin therapy was 3.6% (95% CI, 2.0

295 In the setting of multifactorial risk reduction with statins and other lipid-lowering age

296 The relative risk reductions with dapagliflozin for CV death/HHF (HR,

297 Although relative risk reductions with dapagliflozin were similar for pati

298 Compared with valsartan, absolute risk reductions with sacubitril/valsartan were more prom

299 CVD risk reductions with treatment to BP goals and risk for

300 ased breast reconstruction for malignancy or risk reduction, with any technique, at 81 participating